science
Supreme Court Declines to Hear Pharma Challenges to Medicare Drug Price Program
The U.S. Supreme Court declined to review lawsuits filed by six pharmaceutical companies against the Medicare drug price negotiation program. The White House separately announced an expansion of its TrumpRx discount platform through partnerships with three prescription savings services.
May 19, 9:23 AM·1m read1 source
usatoday.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
U.S. Supreme Court declined to take up lawsuits filed by six pharmaceutical companies challenging the Medicare drug price negotiation program. The companies that brought the suits were AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk.
The court provided no reason for its decision. The drugmakers had already lost their appeals in lower courts. The Supreme Court typically does not accept cases when lower courts have reached the same conclusion.
The White House announced an expansion of its TrumpRx prescription drug discount platform. The update adds more than 600 generic drugs to the site. The expansion was arranged through partnerships with Mark Cuban’s Cost Plus Drug Company, Amazon Pharmacy, and GoodRx.
These services already offer drug savings or low-cost prescription medicines. The partnerships address earlier criticism that many brand-name drugs listed on TrumpRx were already available as generics at lower prices. TrumpRx previously offered fewer drugs than the three partner services.
